CD28/B7 costimulating signal and its clinical significance.
- Author:
Mei-Hua QU
1
Author Information
1. Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
- Publication Type:Journal Article
- MeSH:
Abatacept;
Animals;
Antigen-Presenting Cells;
immunology;
Antigens, CD;
Antigens, Differentiation;
immunology;
B7-1 Antigen;
immunology;
CD28 Antigens;
immunology;
CTLA-4 Antigen;
Humans;
Immunoconjugates;
Signal Transduction;
immunology;
T-Lymphocytes;
immunology
- From:
Journal of Experimental Hematology
2002;10(3):265-267
- CountryChina
- Language:Chinese
-
Abstract:
It is necessary that the two signals are required in T cells activation. The first signal is specific, which T cell receptor could recognize and bind MHC molecule by antigen-presenting cells. Another one is nonspecific, which results from CD28/B7/CTLA4 molecules on T cells and antigen-presenting cells. The both of signals regulate function of T cells such as the activation, proliferation and secreting cytokines. CTLA4 showed the up-regulation in CD28/B7 costimulatory pathway as a negative signal. The immunosuppression could occur by blocking CD28/B7 pathway. It provided useful method for immunotherapy in the autoimmune diseases and graft-versus-host disease. But then, the activation of CD28/B7 could be valuable for the immune system recognizing and eliminating tumor cells.
